HaimaChek’s initial patented product is a percutaneous probe for the in vivo collection of rare circulating tumor cells, circulating endothelial cells (CECs) and Exosomes. The in vivo CTC collection enables early detection of cancer disease progression and the opportunity for real-time monitoring of cancer progression during treatment. HaimaChek delivers a real-time, monitoring by screening >1.5 L blood without removing blood from patients.